A phase 1 study of LOXO-292, a potent and highly selective RET inhibitor, in patients with RET-altered cancers Meeting Abstract
| Authors: | Drilon, A. E.; Subbiah, V.; Oxnard, G. R.; Bauer, T. M.; Velcheti, V.; Lakhani, N. J.; Besse, B.; Park, K.; Patel, J. D.; Cabanillas, M. E.; Johnson, M. L.; Reckamp, K. L.; Boni, V.; Loong, H. H. F.; Schlumberger, M.; Solomon, B.; Cruickshank, S.; Rothenberg, S. M.; Shah, M. H.; Wirth, L. J. |
| Abstract Title: | A phase 1 study of LOXO-292, a potent and highly selective RET inhibitor, in patients with RET-altered cancers |
| Meeting Title: | 54th Annual Meeting of the American Society of Clinical Oncology (ASCO) |
| Journal Title: | Journal of Clinical Oncology |
| Volume: | 36 |
| Issue: | 15 Suppl. |
| Meeting Dates: | 2018 Jun 1-5 |
| Meeting Location: | Chicago, IL |
| ISSN: | 0732-183X |
| Publisher: | American Society of Clinical Oncology |
| Date Published: | 2018-05-20 |
| Start Page: | 6s |
| Language: | English |
| ACCESSION: | WOS:000442916000004 |
| DOI: | 10.1200/JCO.2018.36.15_suppl.102 |
| PROVIDER: | wos |
| Notes: | Meeting Abstract: 102 -- Source: Wos |
